Investor Presentation First Nine Months of 2023
98
Investor presentation
First nine months of 2023
ZEUS trial with ziltivekimab aims to validate the link between
inflammation and major adverse cardiovascular events
R
1:1
Phase 3 CVOT trial ZEUS with ziltivekimab
Investigate CV benefit in 6,200 patients
ziltivekimab 15 mg sc once-monthly + SoC
Placebo sc once-monthly + SoC
Treatment period
(event driven)
3 months
follow-up
Novo NordiskⓇ
Objective
•
•
To investigate the cardiovascular benefit of ziltivekimab in the
treatment of patients with established ASCVD, CKD and
systemic inflammation
Primary endpoints
Time to the first occurrence of 3-point MACE (CV death, non-
fatal MI or non-fatal stroke)
Secondary confirmatory endpoints
.
•
.
Time to first occurrence of expanded MACE¹
Number of hospitalisations for HF or urgent HF visit
Time to occurrence of all-cause mortality
Time to first occurrence of a composite CKD endpoint
1 MACE includes CV death, non-fatal MI or non-fatal stroke, Expanded MACE includes: (CV death, non-fatal MI, non-fatal stroke or hospitalisation for unstable angina pectoris requiring urgent coronary revascularisation)
hsCRP: High-sensitivity C-reactive protein; CVOT: Cardiovascular outcome trial; CV: Cardiovascular; sc: Subcutaneous; SoC: Standard of care; HF: Heart failure; CKD: Chronic kidney disease
Source: Ridker PM, et al., IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial, 17 May 2021View entire presentation